Haleon (HLN) Aperçu de l'action
Haleon plc, avec ses filiales, se consacre à la recherche, au développement, à la fabrication et à la vente de divers produits de santé grand public en Amérique du Nord, en Europe, au Moyen-Orient, en Afrique, en Amérique latine et dans la région Asie-Pacifique. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 6/6 |
| Croissance future | 2/6 |
| Performances passées | 4/6 |
| Santé financière | 2/6 |
| Dividendes | 3/6 |
Récompenses
Analyse des risques
HLN Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Haleon plc Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | UK£3.35 |
| Plus haut sur 52 semaines | UK£4.16 |
| Plus bas sur 52 semaines | UK£2.74 |
| Bêta | 0.25 |
| Variation sur 1 mois | -8.32% |
| Variation sur 3 mois | 0.24% |
| Variation sur 1 an | -8.27% |
| Variation sur 3 ans | 4.58% |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | 8.58% |
Nouvelles et mises à jour récentes
HLN: Lower Forward P E Assumptions Will Pressure Future Share Price
Haleon’s analyst price target has been trimmed by £0.10 to £3.15, as analysts factor in a slightly lower assumed future P/E, alongside recent Street moves that have reduced targets and, in one case, shifted the stock to a Neutral stance. Analyst Commentary Recent Street research on Haleon points to a more cautious tone, with several bearish analysts trimming price targets and reassessing risk around valuation, execution and future growth assumptions.HLN: Cautious Ratings And Execution Progress Will Guide Future Share Price
Haleon’s latest Narrative Update reflects a modest reset in analyst expectations, with the average price target easing in line with recent cuts to £4.30 and £3.65 from major banks as analysts factor in slightly revised assumptions on revenue growth, profit margin and future P/E multiples. Analyst Commentary on Haleon stock Recent Street research on Haleon points to a more cautious tone, with several bearish analysts trimming price targets and, in at least one case, moving to a more neutral stance on the shares.Recent updates
HLN: Lower Forward P E Assumptions Will Pressure Future Share Price
Haleon’s analyst price target has been trimmed by £0.10 to £3.15, as analysts factor in a slightly lower assumed future P/E, alongside recent Street moves that have reduced targets and, in one case, shifted the stock to a Neutral stance. Analyst Commentary Recent Street research on Haleon points to a more cautious tone, with several bearish analysts trimming price targets and reassessing risk around valuation, execution and future growth assumptions.HLN: Cautious Ratings And Execution Progress Will Guide Future Share Price
Haleon’s latest Narrative Update reflects a modest reset in analyst expectations, with the average price target easing in line with recent cuts to £4.30 and £3.65 from major banks as analysts factor in slightly revised assumptions on revenue growth, profit margin and future P/E multiples. Analyst Commentary on Haleon stock Recent Street research on Haleon points to a more cautious tone, with several bearish analysts trimming price targets and, in at least one case, moving to a more neutral stance on the shares.HLN: Mixed Rating Revisions And Execution Risks Will Shape Future Upside
Narrative Update The analyst price target for Haleon has been trimmed by about £0.10 per share. This reflects slightly softer revenue growth assumptions, a higher discount rate, and a lower future P/E, partly offset by firmer profit margin expectations and a mix of recent target moves from Berenberg, Morgan Stanley, and Deutsche Bank.
HLN: Cash Returns And China Expansion Will Support Future Premium Re Rating
Haleon's updated analyst price target of £5.12, which compares with prior targets in the £4.40 to £5.17 range, reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E as analysts reassess the stock following recent mixed target changes across the Street. Analyst Commentary Recent Street research on Haleon presents a mixed picture, but there are clear pockets of optimism as some bullish analysts fine tune their targets around current valuation frameworks.HLN: Cash Returns And China Expansion Will Support Future Re Rating Potential
Narrative Update on Haleon Haleon's analyst price targets have shifted modestly higher, with recent moves such as Berenberg's adjustment to £5.12 from £5.10 and Morgan Stanley's move to £4.40 from £4.20, as analysts point to slightly stronger assumptions for revenue growth and profit margins, along with a marginally lower future P/E. Analyst Commentary Recent research points to a generally constructive tone around Haleon, with several bullish analysts adjusting price targets higher in the latest updates.If EPS Growth Is Important To You, Haleon (LON:HLN) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...HLN: Execution And Cash Returns Will Support Future Re Rating Potential
Haleon's analyst price targets have edged higher, with recent moves such as Berenberg's lift to £5.12 and Morgan Stanley's increase to £4.40. These changes reflect analysts' updated views on slightly stronger revenue growth and profit margin assumptions, alongside modestly adjusted future P/E expectations.HLN: Execution And Cash Returns Will Support Future Re Rating Potential
Haleon's analyst price target has been nudged up from £5.10 to £5.12, reflecting analysts' updated assumptions for slightly higher revenue growth and profit margins, together with recent target increases and rating changes across several research houses. Analyst Commentary Recent Street research on Haleon has been active, with several bullish analysts adjusting their targets and ratings while one major European house turned more cautious.HLN: Execution And New Operating Model Will Support Future Re Rating Potential
The analyst price target for Haleon has inched down from £5.17 to £5.10. This reflects a mix of recent research in which some analysts trimmed expectations on growth and valuation multiples, while others turned more positive on the shares overall.HLN: Execution And Margin Delivery Concerns Will Limit Upside Potential
Our updated analyst price target for Haleon edges lower to £5.10. This reflects modest tweaks to growth and margin assumptions as analysts balance recent target cuts with upgrades, while keeping long term expectations for revenue, profitability and P/E broadly in line with prior views.HLN: Sector Headwinds And Execution Risks Will Constrain Upside Potential
Narrative Update on Haleon The latest analyst price target for Haleon has been revised, reflecting Street research that highlights modestly lower revenue growth assumptions, slightly higher profit margin expectations, and updated sector views following recent upgrades and one downgrade. Analyst Commentary Recent Street research on Haleon has been mixed, with several firms updating their views in quick succession.HLN: Portfolio Execution And New Operating Model Will Support Re Rating
The average analyst price target for Haleon has edged up to £5.17 from £5.10, as analysts cite slightly higher margin assumptions, a modest reset to revenue growth expectations, and supportive recent rating changes and target increases from several firms across the Street. Analyst Commentary Recent Street research on Haleon has been active, with both bullish and more cautious voices weighing in.HLN: Modest Uplift In Outlook Will Balance Execution And Valuation Risks
Analysts have raised their Haleon price target by £0.10, from 507 GBp to 517 GBp. This change reflects updated assumptions for slightly higher revenue growth, a small adjustment to profit margins, and a modestly lower future P/E. Analyst Commentary The latest price target move to 517 GBp signals that at least one research house still sees room for upside in Haleon, but the change is relatively modest.HLN: Rising Confidence In Earnings And Cash Generation Will Support Re Rating
Analysts have nudged their price target on Haleon higher to approximately £5.17 from about £5.07, citing stronger projected revenue growth and a modestly higher future valuation multiple, despite a slightly increased discount rate and marginally lower profit margin assumptions. Analyst Commentary Bullish analysts have reiterated a constructive stance on Haleon, underscored by a series of incremental price target increases that signal growing confidence in the company’s earnings trajectory and cash generation.Is Now The Time To Put Haleon (LON:HLN) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...HLN: Modest Price Objective Increase Will Highlight Balanced Outlook And Execution Risks
Analysts have modestly raised their fair value estimate for Haleon, reflecting a series of incremental price target increases to approximately 517 GBp. This change indicates growing confidence in the company’s accelerating revenue growth and resilient margins, despite a slightly higher discount rate. Analyst Commentary While the latest price target revisions for Haleon are modestly positive, some bearish analysts highlight that the incremental nature of these changes underscores lingering uncertainty around the company’s long term growth trajectory.Are Investors Undervaluing Haleon plc (LON:HLN) By 35%?
Key Insights The projected fair value for Haleon is UK£5.76 based on 2 Stage Free Cash Flow to Equity Current share...Earnings Not Telling The Story For Haleon plc (LON:HLN)
Haleon plc's ( LON:HLN ) price-to-earnings (or "P/E") ratio of 20.5x might make it look like a sell right now compared...Haleon (LON:HLN) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Sensodyne IND 20 And Cost Savings Will Strengthen Future Market Position
Haleon is driving growth through innovation and international expansion in emerging markets, enhancing market share and revenue.Rendement pour les actionnaires
| HLN | GB Pharmaceuticals | GB Marché | |
|---|---|---|---|
| 7D | -8.5% | -3.4% | -0.7% |
| 1Y | -8.3% | 1.8% | 16.1% |
Rendement vs Industrie: HLN a sous-performé le secteur UK Pharmaceuticals qui a rapporté 2.8 % au cours de l'année écoulée.
Rendement vs marché: HLN a sous-performé le marché UK qui a rapporté 17.3 % au cours de l'année écoulée.
Volatilité des prix
| HLN volatility | |
|---|---|
| HLN Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Cours de l'action stable: HLN n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché UK.
Volatilité au fil du temps: La volatilité hebdomadaire de HLN ( 3% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1715 | 24,535 | Brian McNamara | www.haleon.com |
Haleon plc, ainsi que ses filiales, exerce des activités de recherche, de développement, de fabrication et de vente de divers produits de santé grand public en Amérique du Nord, en Europe, au Moyen-Orient, en Afrique, en Amérique latine et dans la région Asie-Pacifique. La société propose des produits d’hygiène bucco-dentaire, tels que des dentifrices, des bains de bouche et des produits d’entretien pour prothèses dentaires sous les marques Sensodyne, Polident, Parodontax et Biotene ; ainsi que des vitamines, des minéraux et des compléments alimentaires sous les marques Centrum, Emergen-C et Caltrate. Elle propose également divers produits en vente libre, notamment des gouttes nasales et des produits contre le rhume, la grippe et les allergies sous les marques Theraflu et Flonase pour les troubles respiratoires ; des analgésiques sous les marques Voltaren, Panadol et Advil ; ainsi que des antiacides et des antihistaminiques sous les marques TUMS, ENO, et Fenistil pour la santé digestive et d’autres troubles.
Haleon plc Résumé des fondamentaux
| HLN statistiques fondamentales | |
|---|---|
| Capitalisation boursière | UK£29.49b |
| Bénéfices(TTM) | UK£1.62b |
| Recettes(TTM) | UK£11.15b |
Le site HLN est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| HLN compte de résultat (TTM) | |
|---|---|
| Recettes | UK£11.15b |
| Coût des recettes | UK£3.84b |
| Marge brute | UK£7.31b |
| Autres dépenses | UK£5.69b |
| Les revenus | UK£1.62b |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 0.18 |
| Marge brute | 65.57% |
| Marge bénéficiaire nette | 14.55% |
| Ratio dettes/capitaux propres | 49.2% |
Quelles ont été les performances à long terme de HLN?
Voir les performances historiques et les comparaisonsDividendes
Le site HLN verse-t-il des dividendes fiables ?
Voir HLN l'historique des dividendes et les indices de référence| Haleon dates des dividendes | |
|---|---|
| Date ex-dividende | Aug 13 2026 |
| Date de paiement du dividende | Sep 17 2026 |
| Jours jusqu'au dividende Ex | 28 days |
| Jours jusqu'à la date de paiement du dividende | 7 days |
Le site HLN verse-t-il des dividendes fiables ?
Voir HLN l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/09 03:25 |
| Cours de l'action en fin de journée | 2026/09/09 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Haleon plc est couverte par 26 analystes. 16 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Iain Simpson | Barclays |
| Warren Ackerman | Barclays |
| Bethan Davies | Berenberg |